UroGen Pharma Ltd. Revenue Disclosure
NOTE 12 – REVENUE FROM PRODUCT SALES
Net product sales consist of the following for the year ended December 31, 2024 and 2023 (in thousands):
| Year Ended December 31, 2024 | Year Ended December 31, 2023 | |||||||
| Jelmyto | $ | 90,398 | $ | 82,713 | ||||
All product sales of Jelmyto are recognized through the Company's arrangements with customers as defined by ASC 606, both of which are third-party national specialty distributors. The Company's largest customer comprises over 90% of product sales throughout the full year 2024, and approximately 80% of accounts receivables at December 31, 2024. Net revenue recognized includes gross revenue and management’s estimate of returns, consideration paid to the customers, chargebacks relating to differences between the wholesale acquisition cost and the contracted price offered to the end consumer, chargebacks relating to 340B drug pricing programs and other government sponsored programs, Medicaid drug rebate programs, the Company’s copay assistance program, and Medicare refunds for discarded drug. The Company estimates these elements of variable consideration based on the contractual or statutory terms governing the arrangements and the Company’s historical experience, and constrains the net revenue recognized for product sales to the value that is not probable to be reversed when the uncertainty associated with the variable consideration is subsequently resolved. Reserves for chargebacks and returns are net settled and recognized as contra accounts receivable while the remaining reserves are recognized within other current liabilities on the consolidated balance sheets. The following table shows the activity with respect to sales reserves for the year ended December 31, 2024 and 2023, in thousands:
| Reserves related to government sponsored programs | Medicare refunds for discarded drug reserve | Other reserves | Total accrued sales reserves | |||||||||||||
| Balance as of December 31, 2022 | $ | 590 | $ | — | $ | 847 | $ | 1,437 | ||||||||
| Changes during 2023 | ||||||||||||||||
| Accruals | 11,110 | 3,451 | 8,807 | 23,368 | ||||||||||||
| Utilizations | (10,638 | ) | — | (8,196 | ) | (18,834 | ) | |||||||||
| Balance as of December 31, 2023 | $ | 1,062 | $ | 3,451 | $ | 1,458 | $ | 5,971 | ||||||||
| Changes during 2024 | ||||||||||||||||
| Accruals | 13,870 | 3,920 | 11,273 | 29,063 | ||||||||||||
| Utilizations | (13,822 | ) | — | (10,785 | ) | (24,607 | ) | |||||||||
| Changes to prior period estimates | (223 | ) | 358 | — | 135 | |||||||||||
| Balance as of December 31, 2024 | $ | 887 | $ | 7,729 | $ | 1,946 | $ | 10,562 | ||||||||
About Revenue Disclosures
Revenue disclosures under ASC 606 explain how a company identifies performance obligations, allocates transaction prices, and determines when revenue is recognized. This section is essential for understanding whether reported revenue reflects genuine economic activity or aggressive accounting choices. Analysts examine the mix of point-in-time versus over-time recognition, which directly affects revenue timing and comparability.
Key signals: rising contract liabilities (deferred revenue) suggest strong future revenue visibility, while declining contract assets may indicate slowing project milestones. Watch for variable consideration estimates — rebates, returns, and performance bonuses that require management judgment. Significant changes in disaggregated revenue by geography or product line can reveal shifting business mix before it appears in headline numbers. Compare revenue growth against contract liability growth to assess sustainability, and scrutinize any changes in the timing of recognition that coincide with earnings pressure.